Expression level of ZNF217 in bladder cancer and its clinical significance
10.3760/cma.j.issn.1673-4181.2019.04.008
- VernacularTitle:膀胱癌组织中ZNF217的表达水平及其临床意义
- Author:
Tieliang HU
1
;
Liang PANG
Author Information
1. 天津市职业病防治院
- Keywords:
Bladder cancer;
Immunohistochemistry;
ZNF217;
Tumor stage;
Recurrence
- From:
International Journal of Biomedical Engineering
2019;42(4):322-325,330
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the expression of ZNF217 protein in bladder cancer tissues and to analyze its clinicopathological characteristics, so as to clarify its clinical significance. Methods The clinicopathological data of 123 patients with bladder cancer who underwent bladder cancer resection were retrospectively analyzed. The expression of ZNF217 protein in bladder cancer tissues and corresponding adjacent tissues was detected by immunohistochemistry, and its correlation with clinical characteristics of patients was analyzed. Results ZNF217 protein was highly expressed in tumor tissues, and the ratio of high expression of tumor tissues was 67.4％, but it was lowly expressed in adjacent tissues. By comparing with clinicopathological features, the expression level of ZNF217 was significantly correlated with tumor T stage and tumor recurrence (all P<0.05), but not correlated with age , gender , tumor differentiation and lymph node metastasis (all P>0.05). The survival analysis showed that patients with high expression of ZNF217 in bladder cancer had significantly shorter overall survival and progression-free survival than those with low ZNF217 expression ( all P<0 . 05 ) . Conclusions ZNF217 is highly expressed in bladder cancer tissues, and its expression level is associated with tumor stage, tumor recurrence and poor prognosis, suggesting that it can be used as a potential therapeutic target for bladder cancer.
